The anti-tumour effect of masitinib/gemcitabine combination treatment was also investigated in CHO cells (constitutive dCK), CHO dCK- cells (deficient dCK), and CHO dCK Rescue cells (partially reconstituted dCK) (Fig. 1d, e). Here, DCK is linked to neoplasm.